Evidence map›Paper›PMID 31380267›Full record

ArticleFrontiers in oncology2019

BAFF/APRIL System Is Functional in B-Cell Acute Lymphoblastic Leukemia in a Disease Subtype Manner.

Eirini Sevdali, Eleni Katsantoni, Cristian R Smulski, Maria Moschovi, Maria Palassopoulou, Eleni-Nefeli Kolokotsa, Nikoletta Argentou, Nikolaos Giannakoulas, Maria Adamaki, Georgios Vassilopoulos and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Eirini SevdaliDepartment of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Eleni KatsantoniBasic Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Cristian R SmulskiCenter for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg im Breisgau, Germany.
Maria MoschoviHematology/Oncology Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece.
Maria PalassopoulouDepartment of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Eleni-Nefeli KolokotsaDepartment of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Nikoletta ArgentouDepartment of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Nikolaos GiannakoulasDepartment of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Maria AdamakiHematology/Oncology Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece.
Georgios VassilopoulosDepartment of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Sophia PolychronopoulouDepartment of Pediatric Hematology/Oncology, "Aghia Sophia" Children's Hospital, Athens, Greece.
Anastasios E GermenisDepartment of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Hermann EibelCenter for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg im Breisgau, Germany.
Matthaios SpeletasDepartment of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
University of Thessaly · GRNational and Kapodistrian University of Athens · GRUniversity Medical Center Freiburg · DEBiomedical Research Foundation of the Academy of Athens · GRChildren's Hospital Agia Sophia · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BAFF, APRIL and their receptors regulate the survival, maturation and homeostasis of mature B-cells. Despite the lack of a functional role of BAFF/APRIL system during normal early B-cell development, previous studies indicated a contribution of these molecules in the pathogenesis of B-lineage acute lymphoblastic leukemia (B-ALL). Here, we evaluated the expression of this system in B-ALL and its involvement in spontaneous and drug-induced apoptosis of B-lymphoblasts, taking into consideration the distinct disease subtypes. We found that BAFFR is the most predominant aberrantly expressed receptor in B-ALL and that its expression, along with BCMA and APRIL, positively correlates with the maturation stage of B-lymphoblasts. Moreover, the binding of the E2A-PBX1 chimeric protein to the

Indexed as

apoptosisBAFFRB-ALLE2A-PBX1glucocorticoids

Identifiers

PMID31380267
PMCPMC6657364
OpenAlexW2950598379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.